ArticleEuropean radiology2026
Bleomycin TACE for symptomatic giant nodular goiter.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesGiant nodular goiters are hypervascular benign thyroid lesions whose surgical resection carries substantial risks. This study evaluates the feasibility, efficacy, and safety of transarterial chemoembolization (TACE) with bleomycin for symptomatic giant nodular goiter. MATERIALS AND
methodsThis single-center retrospective study included patients with giant nodular goiter (≥ 4 cm) treated with TACE using 15,000 U bleomycin and 200-400 μm drug-loaded microspheres between May 2024 and May 2025. Primary outcomes were volumetric reduction and symptom relief. Secondary outcomes included complications and thyroid function changes. Non-parametric paired comparisons were used for statistical analysis.
resultsFifty-one cases (mean age, 58 years [IQR, 42.75-64]) were evaluated. Technical success was achieved in all patients. Median goiter volume decreased from 192.7 cm³ (IQR, 125.4-350.1) to 70.45 cm³ (IQR, 54.04-102.1) at 6-month follow-up (p < 0.0001), representing a median volume reduction rate of 72.13% (IQR, 62.00-78.59). All patients achieved complete symptom remission by 1 month. No major procedure-related adverse events occurred.
conclusionTACE with bleomycin is a safe and feasible minimally invasive option for symptomatic giant nodular goiter, achieving sustained volume reduction and complete symptom remission without major complications. KEY POINTS: Question Symptomatic giant nodular goiters pose substantial surgical risk; effective minimally invasive alternatives with durable volume reduction and symptom relief are lacking. Findings TACE with bleomycin-loaded microspheres achieved a median 72.13% volume reduction at 6 months with 100% symptomatic remission and no major complications in all patients. Clinical relevance TACE with bleomycin provides a safe, minimally invasive treatment option for patients with symptomatic giant nodular goiter who are unwilling or medically unfit for surgery, potentially reducing operative morbidity and improving quality of life.
Indexed as
Identifiers
42287364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.